2024
Polygenic liability for anxiety in association with comorbid anxiety in multiple sclerosis
Kowalec K, Harder A, Dolovich C, Fitzgerald K, Salter A, Lu Y, Bernstein C, Bolton J, Cutter G, Fisk J, Gelernter J, Graff L, Hägg S, Hitchon C, Levey D, Lublin F, McKay K, Patten S, Patki A, Stein M, Tiwari H, Wolinsky J, Marrie R. Polygenic liability for anxiety in association with comorbid anxiety in multiple sclerosis. Annals Of Clinical And Translational Neurology 2024, 11: 1393-1404. PMID: 38715244, PMCID: PMC11187942, DOI: 10.1002/acn3.52025.Peer-Reviewed Original ResearchPolygenic scoresEuropean genetic ancestryUK BiobankAnxious symptomsIncreased oddsGenetic ancestrySelf-reported physician-diagnosedGenetic burdenComorbid anxietyGenome-wide association studiesCase-control designUnited States cohortDirection of effectAssociated with comorbid anxietyPhysician-diagnosedAssociated with disability progressionIndex diseaseStates cohortAnxiety symptomsMeta-analysesAssociation studiesSummary statisticsCurrent symptomsPolygenic liabilityRisk prediction
2022
Associations Between Cannabis Use, Polygenic Liability for Schizophrenia, and Cannabis-related Experiences in a Sample of Cannabis Users
Johnson E, Colbert S, Jeffries P, Tillman R, Bigdeli T, Karcher N, Chan G, Kuperman S, Meyers J, Nurnberger J, Plawecki M, Degenhardt L, Martin N, Kamarajan C, Schuckit M, Murray R, Dick D, Edenberg H, D’Souza D, Di Forti M, Porjesz B, Nelson E, Agrawal A. Associations Between Cannabis Use, Polygenic Liability for Schizophrenia, and Cannabis-related Experiences in a Sample of Cannabis Users. Schizophrenia Bulletin 2022, 49: 778-787. PMID: 36545904, PMCID: PMC10154717, DOI: 10.1093/schbul/sbac196.Peer-Reviewed Original ResearchConceptsCannabis useAlcohol use disorderCognitive difficultiesSchizophrenia polygenic risk scoresFirst cannabis useDaily cannabis useCannabis usersSocial withdrawalUnusual experiencesCannabis involvementPolygenic risk scoresExpected directionGenetic riskUse disordersIndependent replication sampleLike experiencesGenetic liabilityCannabisSchizophreniaPolygenic riskPolygenic liabilityReplication sampleExperienceAnalytic sampleDisordersInterrogating Associations between Polygenic Liabilities and Electroconvulsive Therapy Effectiveness
Loef D, Luykx J, Lin B, van Diermen L, Nuninga J, van Exel E, Oudega M, Rhebergen D, Schouws S, van Eijndhoven P, Verwijk E, Schrijvers D, Birkenhager T, Ryan K, Arts B, van Bronswijk S, Kenis G, Schurgers G, Baune B, Arns M, van Dellen E, Somers M, Sommer I, Boks M, Gülöksüz S, McLoughlin D, Rutten B, Dols A. Interrogating Associations between Polygenic Liabilities and Electroconvulsive Therapy Effectiveness. Biological Psychiatry 2022, 91: s55. DOI: 10.1016/j.biopsych.2022.02.157.Peer-Reviewed Original ResearchTherapy effectivenessPolygenic liability
2020
Polygenic liability for schizophrenia and childhood adversity influences daily‐life emotion dysregulation and psychosis proneness
Pries L, Klingenberg B, Menne‐Lothmann C, Decoster J, van Winkel R, Collip D, Delespaul P, De Hert M, Derom C, Thiery E, Jacobs N, Wichers M, Cinar O, Lin B, Luykx J, Rutten B, van Os J, Guloksuz S. Polygenic liability for schizophrenia and childhood adversity influences daily‐life emotion dysregulation and psychosis proneness. Acta Psychiatrica Scandinavica 2020, 141: 465-475. PMID: 32027017, PMCID: PMC7318228, DOI: 10.1111/acps.13158.Peer-Reviewed Original ResearchConceptsDaily life stressorsChildhood adversityEmotion dysregulationPositive affectPsychosis pronenessMomentary mental statesEcological momentary assessmentChildhood Trauma QuestionnaireGene-environment correlationNegative affectMental statesMomentary assessmentPsychosis expressionTrauma QuestionnaireAdversityAffectYoung adultsStressorsNovel evidencePolygenic liabilityInteraction effectsPronenessSchizophreniaHigh PRSState domain
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply